Source: Government of UK |

Medicines and Healthcare products Regulatory Agency (MHRA) response to contaminated paediatric medicines identified in World Health Organization (WHO) region of Africa

If you have acquired any of these cough syrups (Promethazine Oral Solution, Kofexmalin Baby Cough Syrup, Makoff Baby Cough Syrup and Magrip N Cold Syrup) in The Gambia or through informal routes, do not use them

We strongly encourage anyone to report any suspected side effects associated with their cough syrup to us via our Yellow Card Scheme website

LONDON, United Kingdom, October 7, 2022/APO Group/ --

The products referred to in the WHO Medical Product Alert are not authorised for use in the UK and nor are the active ingredients used in any UK authorised products.

If you have acquired any of these cough syrups (Promethazine Oral Solution, Kofexmalin Baby Cough Syrup, Makoff Baby Cough Syrup and Magrip N Cold Syrup) in The Gambia or through informal routes, do not use them. These are substandard products which are unsafe and their use, especially in children, may result in serious injury or death. If you are unsure, please check with your pharmacist.

If you, or someone you know, have used these products, or suffered any side effect after use, you are advised to seek immediate medical attention. We strongly encourage anyone to report any suspected side effects associated with their cough syrup to us via our Yellow Card Scheme website.

Distributed by APO Group on behalf of Government of UK.